Underused Next-Generation Sequence Testing Revealed in MYLUNG Consortium Study
June 15th 2021Results from the first phase of the broad, collaborative MYLUNG research study in lung cancer provide a close-up look at current biomarker testing rates and turnaround times for patients treated in community practices within The US Oncology Network.
Optimizing Benefit in Targeted Therapies Requires Multipronged Educational Approach
October 25th 2020Much is still unknown about the cancer process and how targeted therapies work on specific tumor vulnerabilities. Providers must closely follow evolving information, especially regarding adverse events.
Evaluating Next Steps for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
September 21st 2020Robert L. Coleman, MD, discusses the next steps for tisotumab vedotin following the presentation of findings from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study in patients with previously treated recurrent or metastatic cervical cancer.
Rationale for Chemotherapy Plus Veliparib in Frontline Treatment of Ovarian Cancers
October 8th 2019Robert L. Coleman, MD, professor of medicine, The University of Texas MD Anderson Cancer Center, explains the rationale for the VELIA trial of veliparib with frontline chemotherapy and maintenance in patients with high-grade ovarian cancer.
Dr. Coleman Discusses the Toxicities Associated With Rucaparib in Patients With Ovarian Cancer
August 18th 2015Robert L. Coleman, MD, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the toxicities associated with rucaparib in patients with ovarian cancer.